Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8-11, 2026) and 5 th International Scientific Congress on SMA (SMA Europe 2026; March 11-14, 2026). “Over the past decade, we have remained steadfast in our pursuit of scientific innovation to support the evolving efficacy needs of the SMA community. We are at an important juncture for our SMA portfolio as we look to bring the high dose regimen of nusinersen to the community and advance salanersen into registrational studies,” said Stephanie Fradette, Pharm,D., Head of the Neuromuscular Development Unit at Biogen. “We are excited to share new longer-term data on high dose nusinersen and salanersen, cross-study neurofilament data, and the design of our salanersen Phase 3 studies.” Highlights of Biogen’s SMA Data Presented at MDA and SMA Europe Nusinersen Exploring Higher Doses of Nusinersen in Spinal Muscular Atrophy (SMA): Integrated Results from the DEVOTE Part B and ONWARD Studies MDA: Poster 101S – Sunday, 8 March – 6:00-8:00 pm ET SMA Europe: P69 – Thursday, 12 March – 4:15-530 pm CEST DEVOTE Part C and ONWARD Integrated Results: Higher Doses of Nusinersen in Nusinersen-Experienced Participants with Spinal Muscular Atrophy (SMA) MDA: Florida 4 - Wednesday, 11 March – 8:15 am ET SMA Europe: P70 – Friday, 13 March – 4:15-530 pm CEST Salanersen STELLAR Phase 3 Studies to Evaluate the Efficacy and Safety of Salanersen in Infants with Spinal Muscular Atrophy (SMA) MDA: Poster 199M - Monday, 9 March – 6:00 – 8:00 pm ET SMA Europe: P72 – Thursday, 12 March – 4:15 – 530 pm CEST The SOLAR study: Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen in Participants Aged 15–60 Years with Spinal Muscular Atrophy (SMA) MDA: Poster 193M - Monday, 9 March 6:00 – 8:00 pm ET SMA Europe: P67 – Thursday, 12 March – 4:15-530 pm CEST Phase 1 Interim Results Evaluating the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Salanersen for Spinal Muscular Atrophy MDA: Florida 4 - Wednesday, 11 March – 8:00 am ET SMA Europe: P71 – Thursday, 12 March – 4:15-530 pm CEST

The release as fetched from its publisher. biogen.com ↗